Edesa Biotech
EDSA
19 hedge funds and large institutions have $507K invested in Edesa Biotech in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
2.11% more ownership
Funds ownership: 1.39% → 3.5% (+2.1%)
5% less funds holding
Funds holding: 20 → 19 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
66% less capital invested
Capital invested by funds: $1.5M → $507K (-$994K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$43K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$13.3K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$8.88K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.93K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$810K |
| 2 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$239K |
| 3 |
State Street
Boston,
Massachusetts
|
-$27.5K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$14.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$15 |
EDSA Hedge Fund Activity: Q4 2023 in Review
19 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q4 2023, worth a combined $507K — down 66% from $1.5M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of EDSA and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.
The largest buyer was Dimensional Fund Advisors, opening a new position worth an estimated $43K. The largest seller was Velan Capital Investment Management, exiting entirely with an estimated $810K sold.
- 19 institutional investors held Edesa Biotech (EDSA) as of Q4 2023, down from 20 in Q3 2023.
- Funds reported $507K of Edesa Biotech stock for Q4 2023, down 66% quarter-over-quarter.
- 4 funds opened new Edesa Biotech positions in Q4 2023 and 5 closed out, a net change of -1 holder.
- The largest Edesa Biotech buyer in Q4 2023 was Dimensional Fund Advisors, an estimated $43K added.
- The largest Edesa Biotech seller in Q4 2023 was Velan Capital Investment Management, an estimated $810K sold.
Based on aggregated 13F filings for Q4 2023.